European Archives of Oto-Rhino-Laryngology

, Volume 273, Issue 9, pp 2419–2426 | Cite as

Comparison of two different steroid treatments with hyperbaric oxygen for idiopathic sudden sensorineural hearing loss

  • Ergun Sevil
  • Sami Bercin
  • Togay Muderris
  • Fatih Gul
  • Muzaffer Kiris


The purpose of the study was to assess the efficacy of the association of intratympanic (IT) steroid and hyperbaric oxygen (HBO) therapy in patients presenting with idiopathic sudden sensorineural hearing loss (ISSNHL), and to compare this protocol with another consisting of intravenous (IV) steroid administration and HBO therapy. A total of 80 patients diagnosed with ISSNHL were included in this prospective trial. Patients were divided into three categories: a mild-to-moderate ISSNHL group with a pure-tone average (PTA) ≤60 decibels (dB), a severe ISSNHL group with a PTA of 60–80 dB, and a profound ISSNHL group with a PTA ≥81 dB. The first protocol consisted of 20 sessions of HBO therapy together with IV methylprednisolone 1 mg/kg body weight and a 10 mg taper every 3 days for 10 days. The second protocol consisted of HBO therapy for 20 sessions, together with an IT injection of dexamethasone at a dose of 4 mg/mL, 0.5–0.7 mL once a day for 7 consecutive days, performed 3 h before the HBO therapy. In the mild-to-moderate ISSNHL patients, the mean hearing gain and successful treatment rate was 19 (0–27) dB and 78.9 %, respectively in the IT + HBO treatment group, and 18 (3–44) dB and 70.5 % in the IV + HBO therapy group. In the severe ISSNHL patients, the mean hearing gain and successful treatment rate was 33 (1–54) dB and 81.8 %, respectively in the IT + HBO treatment group and 33.5 (7–57) dB and 58.2 % in the IV + HBO group. In the profound ISSNHL patients, the mean hearing gain and successful treatment rate was 36 (4–69) dB and 40 %, respectively in the IT + HBO therapy group, and 39.5 (0–92) dB and 72.7 % in the IV + HBO treatment group. The results demonstrated that patients with severe hearing loss success rate was superior in the group submitted to IT + HBO treatment, conversely IV + HBO therapy may be benefit for patients with profound hearing loss. Nevertheless, these clinical results were not statistically significant.


Idiopathic sudden sensorineural hearing loss Hyperbaric oxygen Steroid 


Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.


  1. 1.
    Bethesda MD (2001) Sudden deafness. National Institutes of Health NIH publication. National Institute of Health, New York (4757) Google Scholar
  2. 2.
    Byl FM Jr (1984) Sudden hearing loss: eight years’ experience and suggested prognostic table. Laryngoscope 94:647–661CrossRefPubMedGoogle Scholar
  3. 3.
    Mattox DE, Simmons FB (1977) Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 86:463–480CrossRefPubMedGoogle Scholar
  4. 4.
    Wilson WR, Byl FM, Laird N (1980) The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolaryngol 106:772–776CrossRefPubMedGoogle Scholar
  5. 5.
    Ho HG, Lin HC, Shu MT, Yang CC, Tsai HT (2004) Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 114:1184–1189CrossRefPubMedGoogle Scholar
  6. 6.
    Hong SM, Park CH, Lee JH (2009) Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 141:579–583CrossRefPubMedGoogle Scholar
  7. 7.
    Goto F, Fujita T, Kitani Y, Kanno M, Kamei T, Ishii H (1979) Hyperbaric oxygen and stellate ganglion blocks for idiopathic sudden hearing loss. Acta Otolaryngol 88:335–342CrossRefPubMedGoogle Scholar
  8. 8.
    World Health Organization (1991) Report of the informal working group on prevention of deafness and hearing impairment programme planning WHO/PDH/91. World Health Organization, Geneva. Accessed 8 Mar 2015
  9. 9.
    Plontke SK, Löwenheim H, Mertens J et al (2009) Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 119:359–369CrossRefPubMedGoogle Scholar
  10. 10.
    Stachler RJ, Chandrasekhar SS, Archer SM et al (2012) Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 146:1–35CrossRefGoogle Scholar
  11. 11.
    Garcia Berrocal JR, Ramirez- Camacho R (2000) Immune response and immunopathology of the inner ear: an update. J Laryngol Otol 114(2):101–107PubMedGoogle Scholar
  12. 12.
    Lamm H, Klimpel L (1971) Hyperbaric oxygen therapy in internal ear and vestibular disorders. Preliminary report. HNO 19:363–369PubMedGoogle Scholar
  13. 13.
    Haupt H, Scheibe F, Ludwig C (1993) Changes in cochlear oxygenation, microcirculation and auditory function during prolonged general hypoxia. Eur Arch Otorhinolaryngol 250:396–400CrossRefPubMedGoogle Scholar
  14. 14.
    Lamm K, Lamm C, Arnold W (1998) Effect of isobaric oxygen versus hyperbaric oxygen on the normal and noise-damaged hypoxic and ischemic guinea pig inner ear. Adv Otorhinolaryngol 54:59–85PubMedGoogle Scholar
  15. 15.
    Fattori B, Berrettini S, Casani A, Nacci A, De Vito A, De laco G et al (2001) Sudden hypoacusis treated with hyperbaric oxygen therapy: a controlled study. Ear Nose Throat J 80:655–660PubMedGoogle Scholar
  16. 16.
    Filipo R, Attanasio G, Viccaro M et al (2012) Hyperbaric oxygen therapy with short duration intratympanic steroid therapy for sudden hearing loss. Acta Otolaryngol 132:475–481CrossRefPubMedGoogle Scholar
  17. 17.
    Lamm K, Lamm H, Arnold W (1998) Effect of hyperbaric oxygen therapy in comparison to conventional or placebo therapy or no treatment in idiopathic sudden hearing loss, acoustic trauma, noise-induced hearing loss and tinnitus. A literature survey. Adv Otorhinolaryngol 54:86–99PubMedGoogle Scholar
  18. 18.
    Haynes DS, O’Malley M, Cohen S, Watford K, Labadie RF (2007) Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 117:3–15CrossRefPubMedGoogle Scholar
  19. 19.
    Aoki D, Takegoshi H, Kikuchi S (2006) Evaluation of super-high- dose steroid therapy for sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 134:783–787CrossRefPubMedGoogle Scholar
  20. 20.
    Liu SC, Kang BH, Lee JC et al (2011) Comparison of therapeutic results in sudden sensorineural hearing loss with/without additional hyperbaric oxygen therapy: a retrospective review of 465 audiologically controlled cases. Clin Otolaryngol 36:121–128CrossRefPubMedGoogle Scholar
  21. 21.
    Lee JD, Park MK, Lee CK, Park KH, Lee BD (2010) Intratympanic steroids in severe to profound sudden sensorineural hearing loss as salvage treatment. Clin Exp Otorhinolaryngol 3:122–125CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Topuz E, Yigit O, Cinar U, Seven H (2004) Should hyperbaric oxygen be added to treatment in idiopathic sudden sensorineural hearing loss? Eur Arch Otorhinolaryngol 261:393–396CrossRefPubMedGoogle Scholar
  23. 23.
    Fujimura T, Suzuki H, Shiomori T, Udaka T, Mori T (2007) Hyperbaric oxygen and steroid therapy for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 264:861–866CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ergun Sevil
    • 1
  • Sami Bercin
    • 2
  • Togay Muderris
    • 3
  • Fatih Gul
    • 3
  • Muzaffer Kiris
    • 2
  1. 1.Department of Otorhinolaryngology, Head and Neck SurgeryKaraman State HospitalKaramanTurkey
  2. 2.Department of Otorhinolaryngology, Head and Neck SurgeryYildirim Beyazit University Faculty of MedicineAnkaraTurkey
  3. 3.Department of Otorhinolaryngology, Head and Neck SurgeryAtaturk Training and Research HospitalAnkaraTurkey

Personalised recommendations